Severe hypertension, which may result in intracranial hemorrhage, pulmonary edema, or myocardial necrosis.
Aggravation of tissue ischemia, resulting in gangrene (with high-dose infusion).
Ventricular arrhythmias, especially in patients intoxicated by halogenated or aromatic hydrocarbon solvents or anesthetics.
Tissue necrosis after extravasation (see Item VI.A below for treatment of extravasation).
Anaphylactoid reaction induced by sulfite preservatives in sensitive patients.
Use in pregnancy. FDA Category C (indeterminate). There may be a dose-related effect on uterine blood flow. This does not preclude its acute, short-term use for a seriously symptomatic patient (See Introduction in Section III).